To include your compound in the COVID-19 Resource Center, submit it here.

FDA approves Contrave; requires CV outcomes trial

FDA approved Contrave naltrexone/bupropion from Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) as an adjunct to diet and exercise for chronic weight management in adults with obesity

Read the full 257 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE